What is the expected accretion or dilution to Caleres' earnings per share from this deal?

Short answer:

The press release you provided does not contain any statement about whether the Stuart Weitzman acquisition will be accretive (increase) or dilutive (decrease) to Caleres Inc.’s earnings per share (EPS). Therefore, based on the information given, we cannot specify an expected EPS impact.

Why the EPS effect isn’t disclosed in the excerpt

In many M&A announcements, the acquiring company will often include a line such as “the transaction is expected to be accretive to EPS in FY 2026” or “the deal is expected to be neutral to EPS.” That language is absent here.

How EPS impact is normally estimated (for context)

If you later locate a more detailed filing (e.g., a Form 8‑K, a supplemental press release, or an earnings call transcript), the following pieces of data are typically used to calculate the expected EPS effect:

1. Incremental Net Income – The projected contribution of Stuart Weitzman to Caleres’ net earnings after accounting for integration costs, additional depreciation/amortization, and any interest or tax effects.
2. Financing Mix – How the $108.7 million net purchase price is funded (cash on hand, new debt, equity issuance, or a mix). Debt financing adds interest expense; equity financing dilutes EPS by increasing the share count.
3. Pro‑Forma Share Count – If new shares are issued, the total diluted share count rises, which can offset the earnings boost.
4. Timing – When the acquired brand’s earnings start contributing (often the following fiscal year) versus when the costs are incurred (at closing).
5. Adjustment for Working‑Capital & Contingent Considerations – Final purchase price adjustments can slightly alter the total cost basis.

A typical accretion/dilution calculation looks like:

[
\text{Pro‑forma EPS} = \frac{\text{Caleres FY‑N Net Income (actual)} + \text{Incremental Net Income from acquisition} - \text{Financing Costs}}{\text{Current diluted shares} + \text{New shares issued (if any)}}
]

If Pro‑forma EPS > Current EPS, the deal is accretive; otherwise, it is dilutive.

What you can do next

1. Check Caleres’ recent SEC filings (Form 8‑K, 10‑Q, 10‑K) for a detailed “transaction impact” section. Companies are required to discuss EPS effect if material.
2. Listen to the earnings call or read the accompanying transcript after the acquisition close; management often addresses EPS expectations there.
3. Review analyst reports (e.g., from JPMorgan, Morgan Stanley, etc.) that may have modeled the deal’s impact on EPS based on disclosed financial assumptions.
4. Contact Investor Relations – A direct inquiry to Caleres’ IR team often yields a concise statement on whether the transaction is expected to be EPS‑accretive or dilutive.

Bottom line

From the news snippet you shared, no EPS accretion/dilution guidance is provided. To obtain that information you’ll need to look at more detailed corporate disclosures or analyst commentary that specifically address the earnings impact of the Stuart Weitzman acquisition.